1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Heart Failure Drugs Market
2.2. Global Heart Failure Drugs Market, By By Drug Class, 2023 (US$ Million)
2.3. Global Heart Failure Drugs Market, By By Distribution Channel, 2023 (US$ Million)
2.4. Global Heart Failure Drugs Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023
3. Heart Failure Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Heart Failure Drugs Market Vendors
3.2. Strategies Adopted by Heart Failure Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032
4. Heart Failure Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Heart Failure Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape
5. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Angiotensin-converting Enzyme (ACE) inhibitors
5.3.2. Angiotensin II Receptor Blockers (ARBs)
5.3.3. Beta Blockers
5.3.4. Others (diuretics, inotropes, aldosterone antagonists, digoxin, sinus node inhibitors)
6. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
7. North America Heart Failure Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
7.3. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
7.4.Heart Failure Drugs Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
7.4.1.1.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
7.4.1.2.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
7.4.1.3.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
8. UK and European Union Heart Failure Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
8.3. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
8.4.Heart Failure Drugs Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
8.4.1.1.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
8.4.1.2.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
8.4.1.3.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
8.4.1.4.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
8.4.1.5.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
8.4.1.6.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
9. Asia Pacific Heart Failure Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
9.3. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
9.4.Heart Failure Drugs Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
9.4.1.1.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
9.4.1.2.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
9.4.1.3.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
9.4.1.4.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
9.4.1.5.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
9.4.1.6.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
10. Latin America Heart Failure Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
10.3. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
10.4.Heart Failure Drugs Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
10.4.1.1.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
10.4.1.2.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
10.4.1.3.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
11. Middle East and Africa Heart Failure Drugs Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
11.3. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
11.4.Heart Failure Drugs Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
11.4.1.1.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
11.4.1.2.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Heart Failure Drugs Market: By By Drug Class, 2022-2032, USD (Million)
11.4.1.3.2. Heart Failure Drugs Market: By By Distribution Channel, 2022-2032, USD (Million)
12. Company Profile
12.1.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Novartis AG
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Amgen Inc.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. AstraZeneca Plc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. GlaxoSmithKline plc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Gilead Sciences, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Teva Pharmaceutical Industries Ltd.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Johnson & Johnson Services, Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Daiichi Sankyo Company, Limited
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
